TheraRadar

Pharma Intelligence, Simplified

Landscape → Infectious Disease

Hepatitis B

389 clinical trials

121 active
/
389 total (since 2015)
33
Phase 1 Active
145 total
54
Phase 2 Active
161 total
16
Phase 3 Active
43 total
30
Phase 4 Active
71 total

Top Sponsors (Industry)

Sorted by active Active Done Failed
GSK 7 19 2
Ausper Biopharma Co., Ltd. 7 0 0
Beijing Continent Pharmaceutical Co, Ltd. 5 1 0
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 4 3 1
Brii Biosciences Limited 3 2 0
Aligos Therapeutics 2 1 3
Suzhou HepaThera Biotech Co., Ltd. 2 2 0
Fujian Akeylink Biotechnology Co., Ltd. 2 1 0
LG Chem 2 1 0
Grand Theravac Life Sciences (Nanjing) Co., Ltd. 2 0 0
Gilead 1 10 2
Vir Biotechnology, Inc. 1 4 0
Arbutus Biopharma Corporation 1 2 1
Barinthus Biotherapeutics 1 2 0
Shanghai Zhimeng Biopharma, Inc. 1 2 0
NCT07412236 NOT YET RECRUITING
A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.
Beijing Continent Pharmaceutical Co, Ltd. n=1,208
NCT07090759 RECRUITING
To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment
Fujian Akeylink Biotechnology Co., Ltd. n=526
NCT07343778 NOT YET RECRUITING
A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis
Beijing Continent Pharmaceutical Co, Ltd. n=300
NCT07307586 RECRUITING
A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatitis B
Zhigang Ren n=120
NCT07246889 ACTIVE NOT RECRUITING
Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)
Ausper Biopharma Co., Ltd. n=577
NCT05630807 ACTIVE NOT RECRUITING
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)
GlaxoSmithKline n=981
NCT05630820 ACTIVE NOT RECRUITING
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)
GlaxoSmithKline n=857
NCT04704024 ACTIVE NOT RECRUITING
Reducing Vertical Transmission of Hepatitis B in Africa
University of Alabama at Birmingham n=450
NCT07203118 ACTIVE NOT RECRUITING
A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B
Xi'an Xintong Pharmaceutical Research Co.,Ltd. n=1,444
NCT07095855 NOT YET RECRUITING
A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB
Shanghai Zhimeng Biopharma, Inc. n=1,300
NCT06947499 RECRUITING
A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series
LG Chem n=1,186
NCT05686759 RECRUITING
A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj.
GC Biopharma Corp n=105
NCT03343431 ACTIVE NOT RECRUITING
Antiviral Prophylaxis and Infant Vaccination to Prevent Perinatal Hepatitis B Infection
Institut de Recherche pour le Developpement n=504
NCT06888479 NOT YET RECRUITING
Optimal Timing of Hepatitis B Vaccination After Transplants
Institute of Hematology & Blood Diseases Hospital, China n=1,500
NCT06691412 NOT YET RECRUITING
Obeticholic Acid Among Chronic HBV Patients with Hepatic Steatosis : Clinical and Portal Doppler Outcomes
Assiut University n=100
NCT03489239 ACTIVE NOT RECRUITING
Entecavir to TAF Switch
Thomas Jefferson University n=27
NCT04429295 COMPLETED
Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand
Sanofi Pasteur, a Sanofi Company n=460
NCT04193189 COMPLETED
B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B
National Institute of Allergy and Infectious Diseases (NIAID) n=638
NCT05482282 WITHDRAWN
Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma)
PT Bio Farma
NCT03903796 COMPLETED
Study of the Efficacy and Safety of HS-10234 in Patients With Chronic Hepatitis B Virus Infection
Jiangsu Hansoh Pharmaceutical Co., Ltd. n=963
NCT02836249 COMPLETED
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China)
Gilead Sciences n=181
NCT02836236 COMPLETED
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B (China)
Gilead Sciences n=155
NCT06544551 COMPLETED
Efficacy and Safety Study of Peginterferon Alfacon-2 to Treat Chronic Hepatitis B Virus Infection
Beijing Kawin Technology Share-Holding Co., Ltd. n=336
NCT03887702 TERMINATED
Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors
SWOG Cancer Research Network n=4
NCT04846491 COMPLETED
A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B
Xiamen Amoytop Biotech Co., Ltd. n=475
NCT02600117 COMPLETED
Use of TDF in Patients With Inactive Chronic Hepatitis B Infection
University Health Network, Toronto n=50
NCT02792088 COMPLETED
Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues
IlDong Pharmaceutical Co Ltd n=146
NCT02434848 COMPLETED
A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses
Sheffield Teaching Hospitals NHS Foundation Trust n=13
NCT04490499 COMPLETED
A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013)
Merck Sharp & Dohme LLC n=207
NCT04083157 COMPLETED
Intra-dermal With Topical Imiquimod Pretreatment Versus Intra-muscular Hepatitis B Vaccination in IBD Patients
The University of Hong Kong n=104
NCT02697474 COMPLETED
Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine.
Sanofi Pasteur, a Sanofi Company n=150
NCT02817451 COMPLETED
DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants
Sanofi Pasteur, a Sanofi Company n=53
NCT02428491 COMPLETED
Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth
Sanofi Pasteur, a Sanofi Company n=354
NCT03627507 COMPLETED
Non Inferiority Trial of Locally Manufactured 'Hepa-B' Vaccine in Bangladesh.
International Centre for Diarrhoeal Disease Research, Bangladesh n=158
NCT02555943 COMPLETED
DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)
Humanity and Health Research Centre n=23
NCT02967939 COMPLETED
Efficacy and Safety of DA-2802 in Chronic Hepatitis B Patients
Dong-A ST Co., Ltd. n=123
NCT03408730 COMPLETED
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
VBI Vaccines Inc. n=2,838
NCT02979613 COMPLETED
Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
Gilead Sciences n=490
NCT03393754 COMPLETED
Immunogenicity and Safety of Sci-B-Vac® to Engerix-B® in Adults
VBI Vaccines Inc. n=1,607
NCT02759354 COMPLETED
Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4 to 5 Year Old Children Previously Vaccinated With Vaxelis® or INFANRIX® Hexa (V419-012)
MCM Vaccines B.V. n=754
NCT03307902 COMPLETED
ID HBV Vaccination With Imiquimod in OBI
The University of Hong Kong n=120
NCT02858440 COMPLETED
A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia
GlaxoSmithKline n=235
NCT02003703 COMPLETED
Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected With HIV .
Universidad de Valparaiso n=107

Data: ClinicalTrials.gov